NCT07160647进行中（未招募）2 期
The Efficacy and Safety of Neoadjuvant Therapy With Iparomlimab and Tuvonralimab in Locally Advanced MSI-H/dMMR Colorectal Cancer: An Prospective, Single-Arm Study (Neo-IT)
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 29
- 试验地点
- 1
- 主要终点
- The primary objective of the study is to evaluate the pathologic complete response (pCR) rate
研究概览
简要总结
Immunotherapy may bring revolutionary changes to the preoperative neoadjuvant treatment mode for dMMR/MSI-H locally advanced rectal cancer. According to the existing theory, the use of Iparomlimab and Tuvonralimab may be the best solution. In this study, the investigators will perform single-cell sequencing of participants tissue samples, fully explore the multi-dimensional omics information of tumors and microenvironments, explore the characteristics of the treatment benefit population, and try to construct an efficacy prediction model to screen the treatment benefit population early and implement precise treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients willing to receive neoadjuvant therapy.
- •Age ≥18 years.
- •Histologically confirmed primary colorectal adenocarcinoma (without squamous or sarcomatoid components).
- •Radiologically assessed (contrast-enhanced CT or MRI) as surgically resectable stage IIB-III (limited to cT4 or cN+ per AJCC 8th edition).
- •Confirmed dMMR or MSI-H status by immunohistochemistry or MSI genetic testing.
- •Lesions diagnosed by investigators as amenable to radical resection (R0 resection) without requiring multi-organ resection prior to neoadjuvant therapy.
- •Voluntary participation with signed informed consent.
- •ECOG performance status score of 0-
- •No prior antitumor or immunotherapy before enrollment.
- •Adequate organ and bone marrow function defined as:
- •Hematology: Absolute Neutrophil Count (ANC) ≥1.5×10⁹/L; Platelets (PLT) ≥100×10⁹/L; Hemoglobin (HGB) ≥7.0 g/dL.
- •Liver function: Total Bilirubin (TBIL) ≤1.5×ULN; Alanine Transaminase (ALT) and Aspartate Aminotransferase (AST) ≤3×ULN; Serum Albumin (ALB) ≥28 g/L.
- •Renal function: Serum creatinine ≤1.5×ULN or creatinine clearance ≥50 mL/min; Urine dipstick shows protein <2+; for subjects with baseline urine dipstick protein ≥2+, a 24-hour urine collection must demonstrate protein <1 g.
- •Coagulation: International Normalized Ratio (INR) ≤1.5 and Activated Partial Thromboplastin Time (APTT) ≤1.5×ULN.
- •No severe comorbidities jeopardizing survival (life expectancy <5 years).
- •Fertile female subjects or male subjects with fertile partners must use effective contraception during and for 6 months after treatment. Postmenopausal status or negative urine/serum pregnancy test for premenopausal females.
排除标准
- •1.Prior antitumor therapy for the disease under investigation, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.
- •2.Previous treatment with anti-PD-1, anti-PD-L1, anti-programmed death ligand 2 (PD-L2), or anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) agents, or any other drugs targeting T-cell co-stimulation or immune checkpoint pathways (e.g., OX40, CD137), as well as adoptive cell immunotherapy.
- •3.Concurrent participation in another interventional clinical study. 4.Treatment with any investigational drug or device within 4 weeks prior to the first dose of the study drug.
- •5.Within 7 days before screening laboratory tests: receipt of blood transfusion, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin (EPO), thrombopoietin (TPO), or IL-11 therapy.
- •6.Use of immunosuppressive drugs within 4 weeks before the first dose of the study drug, excluding: intranasal/inhaled topical steroids or local steroid injections (e.g., intra-articular); systemic corticosteroids at doses ≤10 mg/day prednisone or equivalent; corticosteroids as premedication for allergic reactions (e.g., CT scan premedication).
- •7.Use of Chinese herbal medicine with antitumor indications or immunomodulatory drugs (including thymosin, interferon, interleukin, etc.) within 1 week before the first dose of the study drug.
- •8.Receipt of live or attenuated vaccines within 4 weeks before the first dose or anticipated during the study.
- •9.Major surgery (e.g., craniotomy, thoracotomy, or laparotomy) within 4 weeks before the first dose, anticipated need for major surgery during the study (except protocol-defined radical resection for colon cancer), or presence of unhealed wounds, ulcers, or fractures.
研究组 & 干预措施
a combined treatment regimen of immunotherapy and radical surgical resection
Experimental
Eligible patients with advanced MSI-H/dMMR colorectal cancer will receive a combined treatment regimen of immunotherapy and radical surgical resection. The specific procedures are as follows:
Anti-PD-1/CTLA-4 dual immunotherapy (5 mg/kg, IV, D1, Q3W, 4 cycles). Radical surgical resection will be performed after the completion of immunotherapy.
干预措施: Ipalolimab and Tovorilimab (Drug)
结局指标
主要结局
The primary objective of the study is to evaluate the pathologic complete response (pCR) rate
时间窗: Up to 13 weeks (once surgery is done)
Description: pCR was defined as the absence of viable tumour cells in the resected primary tumour specimen and all sampled regional lymph nodes (ypT0N0).
次要结局
- Tumor regression grade(Up to 13 weeks (once surgery is done))
- The proportion of participants who remain progression free at 3 years(Up to 3 years)
- The proportion of participants who remain survival at 3 years(Up to 3 years)
- Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v5.0(Up to 3 years)
- Quality of life of the patients(up to 3 years)
研究者
Sheng Dai
Vice director, Colorectal Surgery
Sir Run Run Shaw Hospital
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)Melanoma MetastaticNCT06586593Centre Hospitalier Universitaire de Besancon77
招募中
2 期
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced MelanomaMelanoma Stage IIIMelanoma Stage IVAdvanced MelanomaMelanomaNCT06295159H. Lee Moffitt Cancer Center and Research Institute90
进行中（未招募）
1 期
Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial - NIVOLEPivolumab in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporationMedDRA version: 20.0Level: PTClassification code 10073071Term: Hepatocellular carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004679-29-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)50
撤回
2 期
Neoadjuvant Immunotherapy to ESCCEsophagus SCCNCT04625543Qilu Hospital of Shandong University
招募中
2 期
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell CarcinomaNeoadjuvant TherapyEsophageal Squamous Cell CarcinomaNCT06354530Army Medical Center of PLA266